Management of hereditary angioedema: 2010 Canadian approach

C1-inhibitor (C1-INH) deficiency is a rare blood disorder resulting in angioedema attacks that are debilitating and may be life-threatening. Prophylaxis and therapy of events has changed since our first Canadian Consensus Conference on the diagnosis, therapy and management of HAE. We have formed the...

Full description

Saved in:
Bibliographic Details
Published in:Allergy, asthma, and clinical immunology Vol. 6; no. 1; p. 20
Main Authors: Bowen, Tom, Brosz, John, Brosz, Kristylea, Hebert, Jacques, Ritchie, Bruce
Format: Journal Article
Language:English
Published: England BioMed Central Ltd 28-07-2010
BioMed Central
BMC
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:C1-inhibitor (C1-INH) deficiency is a rare blood disorder resulting in angioedema attacks that are debilitating and may be life-threatening. Prophylaxis and therapy of events has changed since our first Canadian Consensus Conference on the diagnosis, therapy and management of HAE. We have formed the Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'Angioédème Héréditaire (RCAH) - http://www.haecanada.com to advance care of patients with this disorder in Canada. We here present a review of management of HAE in Canada.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:1710-1492
1710-1484
1710-1492
DOI:10.1186/1710-1492-6-20